

Tuesday, July 9, 2019

Suzanne McGurn
Assistant Deputy Minister and Executive Officer
Ontario Public Drug Programs
Ministry of Health
Government of Ontario
Hepburn Block 9th Flr, 80 Grosvenor St, Toronto, ON M7A 1R3

Sent by email: 'Suzanne.McGurn@Ontario.ca'

Reference: Rifampin Capsules USP 150mg and 300mg

Dear Suzanne,

I hope all is well with you.

As you are probably aware, Bausch Health, Canada Inc. ("Bausch Health") and Sanofi Canada are the only suppliers in Canada that manufacture products containing the active ingredient Rifampin, for the treatment of tuberculosis and meningitis.

Recently, Sanofi announced that their products Rifadin® 150mg and Rifadin® 300mg (Rifampin) are facing a supply shortage as of June 30, 2019 until April 2020.

Consequently, Sanofi's supply shortage is causing a strain on Bausch Health's inventory of Rofact® 300mg (Rifampin 300 mg) and Rofact® 150mg (Rifampin 150mg). We are presently out of stock of Rofact® 300mg and we will be in short supply of Rofact® 150mg until mid-August 2019.

Considering the foregoing, Bausch Health will make the limited quantities of Rofact 150mg available for Hospitals and Government Agencies only. It is highly probable that local pharmacies may currently have inventory of Rofact® 300mg or Rofact 150mg, however if this is not the case, patients should contact their nearest hospital.


Bausch Health would greatly appreciate if you could advise the pharmacists and healthcare professionals, that for patients requiring treatment to contact their nearest hospital, if Rofact is not available at their pharmacy.

Bausch Health, Canada is working diligently to resolve the stock issue of Rofact 300mg.

Product code	Description including strength	Size	GTIN	DIN
060752530118	Rofact Capsules 150mg	100	060752530118	00393444
060752530217	Rofact Capsules 300mg	100	060752530217	00343617

Please do not hesitate to contact our Customer Service Department at 1-800-361-4261 if you require additional information.

Kind regards,



Rosie Childerhose BA, MA
Director, Market Access & Government Affairs. Bausch Health

Copies: Angie Wong, Director, Drug Program Policy and Strategy Branch, Ministry of Health,
Government of Ontario
Martin Barbeau, Vice President, Market Access & Government Affairs, Bausch Health, Canada